<DOC>
	<DOCNO>NCT02852850</DOCNO>
	<brief_summary>Molecular image infliximab antibody FITC potential predict therapeutic response infliximab antibody use personalized medicine ulcerative colitis .</brief_summary>
	<brief_title>In Vivo Molecular Imaging Predicts Therapeutic Response Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients active ulcerative colitis receive infliximab antibody therapy . Patients impaired blood clotting . Patients short bowel syndrome . Patients pregnancy lactation period . Patients receive enema therapy within 1 month inclusion study , antiTNF therapy within last 12 month . Patients participate another clinical trial administrate investigational drug within 4 month prior screen visit . Patients moderate severe heart failure , active tuberculosis acute infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>